US Stock Market Move | Gilead Sciences, Inc. (GILD.US) rose by over 5%, with a nearly 17-fold increase in net profit in 2025 compared to the previous year.

On Wednesday, Gilead Sciences, Inc. (GILD.US) rose more than 5%, closing at $155.54, reaching a new all-time high. The latest financial report released by Gilead Sciences, Inc. shows that the company's full-year revenue for 2025 reached $29.443 billion, a year-over-year increase of 2.4%; the net profit attributable to the listed company was $8.51 billion, a year-over-year increase of approximately 16.73 times, and the non-GAAP diluted earnings per share was $8.15, a year-over-year increase of 77%. Gilead Chairman and CEO Daniel O'Day introduced that last year was a fruitful year for the company, with the successful launch of the first semi-annual HIV prevention therapy Yeztugo worldwide. Biktarvy and Descovy continued to grow, laying a solid foundation for the company's growth.